Neurobiological and psychiatric consequences of child abuse and neglect

The effects of early‐life trauma and its consequences for the treatment of depression are reviewed. The prevalence and clinical sequelae of early sexual and physical abuse, neglect and parental loss are described. An overview of preclinical studies that help guide clinical research and practice is p...

Full description

Saved in:
Bibliographic Details
Published in:Developmental psychobiology Vol. 52; no. 7; pp. 671 - 690
Main Authors: Heim, Christine, Shugart, Margaret, Craighead, W. Edward, Nemeroff, Charles B.
Format: Journal Article
Language:English
Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01-11-2010
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effects of early‐life trauma and its consequences for the treatment of depression are reviewed. The prevalence and clinical sequelae of early sexual and physical abuse, neglect and parental loss are described. An overview of preclinical studies that help guide clinical research and practice is presented. Human clinical studies on the neurobiological consequences of early trauma are summarized. Moderating factors, such as genetic variation and sex differences, are discussed. The few current treatment outcome studies relevant to this research area are described. Guidance for the management of patients with depression and a history of child abuse and neglect are provided. Most patients who have experienced early traumatic experiences are likely best treated with a combination of psychotherapy and pharmacotherapy. This review is dedicated to the memory of Seymour Levine who pioneered the field of early experience research and to a considerable extent inspired the clinical studies described in this review. © 2010 Wiley Periodicals, Inc. Dev Psychobiol 52: 671–690, 2010.
Bibliography:istex:850C66B163BAE1EF76ACFD3E34075CAB49C58532
Financial disclosures-Craighead, W. Edward: Dr. Craighead's research is funded by NIMH. He receives book royalties from John Wiley & Sons Publishers. He is a stockholder of NovaDel Pharma stock. He serves on the board of directors of Hugarheill, an Icelandic LLC. He is a Senior Fellow of the Emory Center for the Study of Law and Religion. Christine Heim: Dr. Heim has received or receives funding or fees from NIMH, NARSAD, ADAA, Center for Behavioral Neuroscience, CDC, Eli Lilly, Novartis, and CeNeRx. Charles B. Nemeroff: Scientific Advisory Board: AFSP; AstraZeneca; NARSAD, PharmaNeuroboost, CeNeRx; Stockholder or Equity: Corcept; Revaax; NovaDel Pharma; CeNeRx, PharmaNeuroboost, Mt. Cook Pharma; Board of Directors: American Foundation for Suicide Prevention (AFSP); George West Mental Health Foundation; NovaDel Pharma, Mt. Cook Pharma, Inc.; Patents: Method and devices for transdermal delivery of lithium (US 6,375,990 B1) Method to estimate serotonin and norepinephrine transporter occupancy after drug treatment using patient or animal serum (provisional filing April 2001).
ark:/67375/WNG-43X11RPT-D
ArticleID:DEV20494
Financial disclosures—Craighead, W. Edward: Dr. Craighead's research is funded by NIMH. He receives book royalties from John Wiley & Sons Publishers. He is a stockholder of NovaDel Pharma stock. He serves on the board of directors of Hugarheill, an Icelandic LLC. He is a Senior Fellow of the Emory Center for the Study of Law and Religion. Christine Heim: Dr. Heim has received or receives funding or fees from NIMH, NARSAD, ADAA, Center for Behavioral Neuroscience, CDC, Eli Lilly, Novartis, and CeNeRx. Charles B. Nemeroff: Scientific Advisory Board: AFSP; AstraZeneca; NARSAD, PharmaNeuroboost, CeNeRx; Stockholder or Equity: Corcept; Revaax; NovaDel Pharma; CeNeRx, PharmaNeuroboost, Mt. Cook Pharma; Board of Directors: American Foundation for Suicide Prevention (AFSP); George West Mental Health Foundation; NovaDel Pharma, Mt. Cook Pharma, Inc.; Patents: Method and devices for transdermal delivery of lithium (US 6,375,990 B1) Method to estimate serotonin and norepinephrine transporter occupancy after drug treatment using patient or animal serum (provisional filing April 2001).
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Feature-3
ObjectType-Review-1
ISSN:0012-1630
1098-2302
1098-2302
DOI:10.1002/dev.20494